Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
4,794 total articles
Moderna's pivot away from COVID-only revenues into oncology and a planned flu launch gives it a clearer multi-year path than many vaccine peers. At $44.64 today and a market cap near $17.4B, the risk/reward favors a measured long with defined stops while Novavax remains a qualitative comparator given limited public data in this note.
Hims & Hers (HIMS) is repositioning from a direct-to-consumer retailer into a multi-service telehealth platform. At about $28.72 today and a market cap near $6.5B, the stock trades at a premium multiple but shows improving unit economics, positive free cash flow, and a large, addressable market in weight management, mental health and primary care. …
Nvidia remains the dominant supplier of AI infrastructure with accelerating data-center demand, rare margins and cash generation, and bullish technicals. At roughly $192, the shares offer a compelling risk/reward for a long trade with a $260 target over a 180 trading-day horizon. Valuation is rich on paper, but growth and cash flow justify a discip…
Alphabet ($GOOGL) looks positioned to outperform into and through its upcoming Q4 report. The stock trades near $338 with a ~$4.08 trillion market cap, robust free cash flow of $73.6B and a clean balance sheet. Recent headlines around AI, AR hardware, and cloud traction make this a sensible upgrade to a long trade into earnings, paired with a stric…
Netflix is down sharply from its 2025 highs after the proposed acquisition of Warner Bros. Discovery and a broader tech sell-off. The core streaming business remains profitable with strong cash generation and healthy margins; the market has largely priced in deal execution and leverage risk. For disciplined traders, this creates a defined-risk long…
HubSpot (HUBS) has been knocked down after guidance concerns and sector rotation, but the company still generates meaningful free cash flow, carries no debt, and sits at oversold technicals. This trade targets a mid-term rebound while protecting capital with a tight stop under recent lows.
Molina Healthcare ($MOH) sold off after CMS proposed a 0.09% Medicare Advantage rate increase for 2027 on 01/27/2026. The pullback creates a mid-term swing entry into a company with a $9.5B market cap, P/E near 11, and deep Medicaid exposure (roughly 75% of revenue). We recommend buying the dip with a clear entry, stop and target and a 45-trading-d…
Palladyne AI pairs hardware robotics with autonomy software and a recent cybersecurity partnership. The market is pricing the company like a growth software story while revenue proof is still emerging. We think a mid-term long trade captures re-rating potential from new contract wins and recurring software sales, while respect for headline valuatio…
Microsoft has been weak on AI anxiety headlines, but beneath the headlines the company still posts strong cloud growth, a massive $625B commercial backlog, $77.4B in free cash flow and a fortress balance sheet. The market is trading off near-term execution fears; that creates a tactical buy opportunity for a swing trade with defined risk.
EVgo is showing early signs of an earnings-quality turnaround: record charging revenue, faster station deployment via prefabricated skids and rapid Autocharge+ adoption. With an enterprise value of ~$453M, improving unit economics and a healthy cash buffer, EVgo looks positioned for a rating upgrade. This trade plan targets a move to $4.50 over the…
Bitdeer is trading like a pure bitcoin miner after a bruising R&D miss and class‑action headlines. The company still controls datacenter capacity, has visible short interest and technical support, and — critically — is pursuing a full‑stack compute play (SEAL04 ASIC + systems) that the market has largely discounted. I’m recommending a mid‑term swin…
OCANF shows bullish technicals: price trading above the 10/20/50-day moving averages, an RSI under 70, and a bullish MACD. Short interest has collapsed from multi-million share levels to ~318k shares with days-to-cover at 7.6, setting up a measured long where a short squeeze can amplify gains. Entry $36.77, stop $32.50, target $45.00 for a mid-term…
TXO Partners (TXO) trades near $12 with a 16%+ distribution yield, a low debt-to-equity ratio of 0.37 and an EV/EBITDA of ~10.6. This trade idea targets a mid-term re-rate into the low-teens/teens driven by yield-hungry buyers and improving operational headlines. Entry $11.98, stop $10.30, target $15.00, horizon: mid term (45 trading days).
InfuSystem (INFU) is a cash-generative provider of home infusion and device services trading at about $8.00. Modest growth, improving margins and a sensible balance sheet make it a reasonable mid-term long trade if regulatory clarity or reimbursement tailwinds materialize. Entry $7.95, stop $7.20, target $10.50 over ~45 trading days.
Viemed Healthcare is trading at reasonable multiples versus its cash-flow profile and operating momentum. The combination of a modest enterprise value, positive free cash flow and an improving patient and revenue backdrop supports a mid-term long trade with a well-defined entry, stop and target.
Cadence (CDNS) remains a clear beneficiary of the AI-driven demand for simulation, verification and semiconductor IP, yet today’s pullback after a sharp run leaves valuation stretched. We lay out a mid-term swing trade that leans long into the company’s secular momentum while protecting capital with a tight stop.
Shift4 Payments has a credible growth narrative and healthy free cash flow, but elevated short interest, weakening technical momentum, and meaningful leverage make it an attractive candidate for a mid-term short. This trade targets a breakdown to $45.00 from an entry at $59.00 with a stop at $68.00 over a 45-trading-day horizon.
Monster Beverage (MNST) is the dominant pure-play energy drink franchise with strong margins, roughly $2.0B in free cash flow and no net debt. The stock trades at a premium - P/E ~46 and EV/EBITDA ~32 - which already prices in continued growth. This trade idea recommends a cautious long entry on controlled weakness with a mid-term target that leave…
Civeo (CVEO) trades at roughly $25 with a market cap near $290M, EV/EBITDA ~6.7 and price-to-sales ~0.46. Negative EPS masks an asset-light lodging business that generates predictable cash flow when mining and energy activity cycles up. A thoughtful buyback program and a compressed valuation argue for a re-rating. This trade idea outlines an entry …
Micron ripped higher after CEO Sanjay Mehrotra said demand is outpacing supply through 2027 and the company is prioritizing enterprise memory (HBM/SSD) over consumer DRAM. Fundamentals - including healthy free cash flow, low leverage, and a dramatic 12-month recovery from a $61 low - support a momentum trade. This piece lays out an actionable entry…
LendingClub plunged ~10% intraday after an earnings beat on 01/29/2026 despite giving stronger-than-consensus 2026 guidance. The move looks driven by short-term disappointment over an accounting shift rather than fundamentals. With a market cap under $2.0B, low PB, and double-digit originations guidance from investor day, this is a tactical long (s…
Micron is trading near all-time highs after a dramatic recovery from 2025 lows. Strong AI-driven memory demand, improving margins, and healthy cash flow support the move. The technicals show bullish momentum; the trade below lays out a mid-term plan with entry, stop and target while flagging the key risks that could derail the rally.
Vistra (VST) combines solid free cash flow, a growing role in AI/tech power contracts, and near-term nuclear upside. The stock looks poised for further gains from 2026 catalysts, but stretched multiples and operational risks mean better risk/reward opportunities may exist elsewhere. This trade plan offers a disciplined entry at $163.00, a $190 targ…
General Dynamics (GD) is pullbacking into technical support after recent strength; fundamentals and defense-market tailwinds support a mid-term swing trade. Entry $350, target $380, stop $335 — a pragmatic play targeting upside above the January highs while limiting downside risk.
Unicycive (UNCY) is a speculative buy ahead of an expected NDA resubmission and renewed FDA inspection focus. The company trades at a sub-$200M market cap with clear binary catalysts, a compact share float, and signs of improving technical momentum. This trade plan targets a mid-term recovery while acknowledging elevated regulatory and legal risk.
